Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1989 9
1990 3
1991 5
1992 2
1993 12
1994 9
1995 4
1996 12
1997 11
1998 8
1999 10
2000 4
2001 6
2002 12
2003 8
2004 12
2005 11
2006 6
2007 12
2008 19
2009 16
2010 14
2011 14
2012 24
2013 26
2014 21
2015 16
2016 18
2017 12
2018 11
2019 13
2020 11
2021 7
Text availability
Article attribute
Article type
Publication date

Search Results

348 results
Results by year
Filters applied: . Clear all
Page 1
Bone marrow niches in haematological malignancies.
Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M, Krause DS. Méndez-Ferrer S, et al. Among authors: gribben jg. Nat Rev Cancer. 2020 May;20(5):285-298. doi: 10.1038/s41568-020-0245-2. Epub 2020 Feb 28. Nat Rev Cancer. 2020. PMID: 32112045 Review.
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators. Leonard JP, et al. Among authors: gribben jg. J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21. J Clin Oncol. 2019. PMID: 30897038 Free PMC article. Clinical Trial.
How and when I do allogeneic transplant in CLL.
Gribben JG. Gribben JG. Blood. 2018 Jul 5;132(1):31-39. doi: 10.1182/blood-2018-01-785998. Epub 2018 May 11. Blood. 2018. PMID: 29752258 Free PMC article. Review.
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D, Fegan C, McCaig A, Schuh A, Pettitt A, Gribben JG, Patten PEM, Devereux S, Bloor A, Fox CP, Forconi F, Munir T. Hillmen P, et al. Among authors: gribben jg. J Clin Oncol. 2019 Oct 20;37(30):2722-2729. doi: 10.1200/JCO.19.00894. Epub 2019 Jul 11. J Clin Oncol. 2019. PMID: 31295041 Free PMC article. Clinical Trial.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. Moreno C, et al. Among authors: gribben jg. Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3. Lancet Oncol. 2019. PMID: 30522969 Clinical Trial.
Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells.
Wong PP, Muñoz-Félix JM, Hijazi M, Kim H, Robinson SD, De Luxán-Delgado B, Rodríguez-Hernández I, Maiques O, Meng YM, Meng Q, Bodrug N, Dukinfield MS, Reynolds LE, Elia G, Clear A, Harwood C, Wang Y, Campbell JJ, Singh R, Zhang P, Schall TJ, Matchett KP, Henderson NC, Szlosarek PW, Dreger SA, Smith S, Jones JL, Gribben JG, Cutillas PR, Meier P, Sanz-Moreno V, Hodivala-Dilke KM. Wong PP, et al. Among authors: gribben jg. Cell. 2020 Jun 11;181(6):1346-1363.e21. doi: 10.1016/j.cell.2020.02.003. Epub 2020 May 29. Cell. 2020. PMID: 32473126
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Cheson BD, et al. Among authors: gribben jg. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584548 Clinical Trial.
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D. Rosenwald A, et al. Among authors: gribben jg. J Clin Oncol. 2019 Dec 10;37(35):3359-3368. doi: 10.1200/JCO.19.00743. Epub 2019 Sep 9. J Clin Oncol. 2019. PMID: 31498031 Free article.
348 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page